litlas
Log inCreate account

Thomas A. Davis

Active 1986–2024

67
Papers
19,037
Citations
56
h-index
67
i10-index

Citations

Citations per year for Thomas A. Davis1986: 1 citations1987: 14 citations1988: 7 citations1989: 7 citations1991: 3 citations1992: 2 citations1994: 3 citations1996: 3 citations1997: 10 citations1998: 39 citations1999: 67 citations2000: 68 citations2001: 96 citations2002: 97 citations2003: 106 citations2004: 140 citations2005: 185 citations2006: 164 citations2007: 195 citations2008: 205 citations2009: 146 citations2010: 140 citations2011: 139 citations2012: 125 citations2013: 106 citations2014: 112 citations2015: 155 citations2016: 139 citations2017: 179 citations2018: 133 citations2019: 398 citations2020: 461 citations2021: 424 citations2022: 414 citations2023: 266 citations2024: 374 citations2025: 149 citations2026: 3 citations1990: no citations, so this year is not shown1993: no citations, so this year is not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,108 citing papers, 34.5% of this breakdownChina: 580 citing papers, 9.5% of this breakdownGermany: 328 citing papers, 5.4% of this breakdownUnited Kingdom: 308 citing papers, 5% of this breakdownFrance: 249 citing papers, 4.1% of this breakdownItaly: 226 citing papers, 3.7% of this breakdownCanada: 176 citing papers, 2.9% of this breakdownJapan: 167 citing papers, 2.7% of this breakdownNetherlands: 166 citing papers, 2.7% of this breakdownSwitzerland: 161 citing papers, 2.6% of this breakdownAustralia: 156 citing papers, 2.6% of this breakdownIndia: 144 citing papers, 2.4% of this breakdown
0%34.5%Other 21.9%

Institutions

Fields

  • Medicine57%
  • Immunology and Microbiology21.4%
  • Biochemistry, Genetics and Molecular Biology8.9%
  • Environmental Science4%
  • Engineering2%
  • Agricultural and Biological Sciences1.8%
  • Other4.9%

Topics

  • Immunotherapy and Immune Responses8.7%
  • Cancer Immunotherapy and Biomarkers7.1%
  • CAR-T cell therapy research5.2%
  • Immune Cell Function and Interaction4.8%
  • Glioma Diagnosis and Treatment4.1%
  • T-cell and B-cell Immunology3.8%
  • Other66.3%

Coauthors

All papers

Open in search
  1. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

    Authors: Michael Weller, Nicholas Butowski, David Tran, Lawrence D. Recht, Michael Lim, Hal W. Hirte, Lynn S. Ashby, Laszlo Mechtler, Samuel Goldlust, Fábio M. Iwamoto, Jan Drappatz, Donald M. O’Rourke, Mark Wong, Mark G. Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D. Turner, Michael Yellin, Tibor Keler, Thomas A. Davis, Roger Stupp, John H. Sampson, Nicholas Butowski, Jian Campian, Lawrence D. Recht, Michael Lim, Lynn S. Ashby, Jan Drappatz, Hal W. Hirte, Fábio M. Iwamoto, Laszlo Mechtler, Samuel Goldlust, Kevin Becker, Gene H. Barnett, Garth Nicholas, Annick Desjardins, Tara Benkers, Naveed Wagle, Morris D. Groves, Santosh Kesari, Zsolt Horváth, Ryan Merrell, Richard Curry, James O’Rourke, David M. Schuster, Mark Wong, Maciej M. Mrugała, Randy Jensen, John Trusheim, Glenn J. Lesser, Karl Bélanger, Andrew E. Sloan, Benjamin Purow, Karen Fink, Jeffrey J. Raizer, Michael Schulder, Suresh Nair, Scott Peak, James Perry, Alba A. Brandes, Michael Weller, Nimish Mohile, Joseph Landolfi, Jon Olson, Gaetano Finocchiaro, Ross Jennens, Paul DeSouza, Bridget A. Robinson, Marka R. Crittenden, Kent C. Shih, Alexandra Flowers, Shirley Ong, Jennifer Connelly, Costas G. Hadjipanayis, Pierre Giglio, Frank E. Mott, David Mathieu, N. Lessard, Sanchez Juan Sepulveda, József Lövey, Helen Wheeler, Po-Ling Inglis, Claire Hardie, Daniela A. Bota, Maciej S. Lesniak, Jana Portnow, Bruce Frankel, Larry Junck, Reid C. Thompson, Lawrence Berk, John Paul McGhie, David Macdonald, Frank Saran, Riccardo Soffietti, Deborah T. Blumenthal, Sá Barreto Costa Marcos André de, Anna K. Nowak and 93 more - The Lancet Oncology 2017 cited by 1,113

  2. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

    Authors: David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke, David Tran, Karen Fink, Burt Nabors, Gordon Li, Daniela A. Bota, Rimas V. Lukas, Lynn S. Ashby, J. Paul Duic, Maciej M. Mrugała, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A. Green, Michael Yellin, Christopher D. Turner, Tibor Keler, Thomas A. Davis, John H. Sampson - Clinical Cancer Research 2020 cited by 177

  3. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    Authors: James M. Schuster, R. K. Lai, Lawrence D. Recht, David A. Reardon, Nina A. Paleologos, Morris D. Groves, Maciej M. Mrugała, Randy L. Jensen, Joachim M. Baehring, Andrew E. Sloan, Gerald E. Archer, D. D. Bigner, Scott Cruickshank, J. A. Green, Tibor Keler, Thomas A. Davis, Amy B. Heimberger, John H. Sampson - Neuro-Oncology 2015 cited by 417

  4. Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification

    Authors: Shailesh Agarwal, Shawn Loder, Cameron Brownley, David Cholok, Laura Mangiavini, John Li, Christopher Breuler, Hsiao Hsin Sung, Shuli Li, Kavitha Ranganathan, Joshua M. Peterson, Ronald G. Tompkins, David N. Herndon, Wenzhong Xiao, Dolrudee Jumlongras, Bjørn R. Olsen, Thomas A. Davis, Yuji Mishina, Ernestina Schipani, Benjamin Lévi - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 223

  5. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

    Authors: F. Stephen Hodi, Martín C. Mihm, Robert J. Soiffer, Frank G. Haluska, Marcus O. Butler, Michael V. Seiden, Thomas A. Davis, Rochele Henry-Spires, Suzanne MacRae, Ann Willman, Robert F. Padera, Michael T. Jaklitsch, Sridhar Shankar, Teresa C. Chen, Alan J. Korman, James P. Allison, Glenn Dranoff - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 997

  6. Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

    Authors: Madhav V. Dhodapkar, Mario Sznol, Biwei Zhao, Ding Wang, Richard D. Carvajal, Mary Louise Keohan, Ellen Chuang, Rachel E. Sanborn, Jose Lutzky, John D. Powderly, Harriet M. Kluger, Sheela Tejwani, Jennifer Green, Venky Ramakrishna, Andrea Crocker, Laura Vitale, Michael Yellin, Thomas A. Davis, Tibor Keler - Science Translational Medicine 2014 cited by 357

  7. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

    Authors: Nina Bhardwaj, Philip Friedlander, Anna C. Pavlick, Marc S. Ernstoff, Brian Gastman, Brent A. Hanks, Brendan D. Curti, Mark R. Albertini, Jason J. Luke, Ana-Belén Blázquez, Sreekumar Balan, Davide Bedognetti, Joseph Beechem, Andrea Crocker, Leonard D’Amico, Patrick Danaher, Thomas A. Davis, Thomas Hawthorne, Bruce W. Hess, Tibor Keler, Lisa Lundgren, Chihiro Morishima, Nirasha Ramchurren, Darawan Rinchai, Andres Μ. Salazar, Bob Salim, Elad Sharon, Laura Vitale, Ena Wang, Sarah Warren, Michael Yellin, Mary L. Disis, Martin A. Cheever, Steven P. Fling - Nature Cancer 2020 cited by 126

  8. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

    Authors: David G. Maloney, Antonio J Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, Kenneth A. Foon, Tina-Marie Liles, B.K. Dallaire, Ken Wey, Ivor Royston, Thomas A. Davis, Ronald Levy - Blood 1997 cited by 1,697

  9. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Authors: Giao Q. Phan, James Chih‐Hsin Yang, Richard M. Sherry, Patrick Hwu, Suzanne L. Topalian, Douglas J. Schwartzentruber, Nicholas P. Restifo, Leah Haworth, Claudia A. Seipp, Linda J. Freezer, Kathleen E. Morton, Sharon Mavroukakis, Paul H. Duray, Seth M. Steinberg, James P. Allison, Thomas A. Davis, Steven A. Rosenberg - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 1,573

  10. Orthopaedic osseointegration: Implantology and future directions

    Authors: Archie L. Overmann, Conrado Aparicio, John T. Richards, Isha Mutreja, Nicholas G. Fischer, Sean M. Wade, Benjamin K. Potter, Thomas A. Davis, Joan E. Bechtold, Jonathan A. Forsberg, Devaveena Dey - Journal of Orthopaedic Research® 2019 cited by 131

  11. A review of the biochemistry of heavy metal biosorption by brown algae

    Authors: Thomas A. Davis, Bohumil Volesky, Alfonso Mucci - Water Research 2003 cited by 2,375

  12. Heterotopic Ossification: Basic-Science Principles and Clinical Correlates

    Authors: Kavitha Ranganathan, Shawn Loder, Shailesh Agarwal, Victor W. Wong, Jonathan A. Forsberg, Thomas A. Davis, Stewart C. Wang, Aaron W. James, Benjamin Lévi - Journal of Bone and Joint Surgery 2015 cited by 387

  13. The traumatic bone: trauma-induced heterotopic ossification

    Authors: Devaveena Dey, B. M. Wheatley, David Cholok, Shailesh Agarwal, Paul B. Yu, Benjamin Lévi, Thomas A. Davis - Translational research 2017 cited by 144

  14. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

    Authors: Denise A. Yardley, Robert Weaver, Michelle Melisko, Mansoor N. Saleh, Francis P. Arena, Andres Forero, Tessa Cigler, Alison Stopeck, Dennis L. Citrin, Ira A. Oliff, Rebecca Bechhold, Randa Loutfi, Agustin A. García, Scott Cruickshank, Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael Yellin, Thomas A. Davis, Linda T. Vahdat - Journal of Clinical Oncology 2015 cited by 189

  15. Topical advances in wound care

    Authors: Alexander Stojadinovic, Jay W. Carlson, Gregory S. Schultz, Thomas A. Davis, Eric A. Elster - Gynecologic Oncology 2008 cited by 145

  16. Scleraxis-Lineage Cells Contribute to Ectopic Bone Formation in Muscle and Tendon

    Authors: Shailesh Agarwal, Shawn Loder, David Cholok, Joshua M. Peterson, John Li, Christopher Breuler, R. Cameron Brownley, Hsiao Hsin Sung, Michael T. Chung, Nobuhiro Kamiya, Shuli Li, Bin Zhao, Vesa Kaartinen, Thomas A. Davis, Ammar T. Qureshi, Ernestina Schipani, Yuji Mishina, Benjamin Lévi - Stem Cells 2016 cited by 113

  17. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth

    Authors: Hubert Lam, Lisa K. McNeil, Hanna Starobinets, Victoria L. DeVault, Roger B. Cohen, Przemyslaw Twardowski, Melissa L. Johnson, Maura L. Gillison, Mark N. Stein, Ulka N. Vaishampayan, Arthur P. DeCillis, James J. Foti, Vijetha Vemulapalli, Emily Tjon, Kyle Ferber, Daniel B. DeOliveira, Wendy Broom, Parul Agnihotri, Elizabeth M. Jaffee, Kwok‐Kin Wong, Charles G. Drake, Pamela M. Carroll, Thomas A. Davis, Jessica B. Flechtner - Cancer Discovery 2021 cited by 57

  18. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

    Authors: Michael Weller, Kerstin Kaulich, Bettina Hentschel, Joerg Felsberg, Dorothee Gramatzki, Torsten Pietsch, Matthias Simon, Manfred Westphal, Gabriele Schackert, J. C. Tonn, Andreas von Deimling, Thomas A. Davis, William A. Weiss, Markus Loeffler, Guido Reifenberger, for the German Glioma Network - International Journal of Cancer 2013 cited by 118

  19. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma

    Authors: Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet M. Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, Thomas A. Davis, Mario Sznol, Patrick Hwu - Journal of Clinical Oncology 2014 cited by 98

  20. Alarming Cargo: The Role of Exosomes in Trauma-Induced Inflammation

    Authors: Sarah A. Walsh, Benjamin W. Hoyt, Cassie J. Rowe, Devaveena Dey, Thomas A. Davis - Biomolecules 2021 cited by 39

  21. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

    Authors: Allan D. Kirk, David M. Harlan, Nicholas Armstrong, Thomas A. Davis, Yinchen Dong, Gary S. Gray, Xuening Hong, David W. Thomas, John H. Fechner, Stuart J. Knechtle - National Academy of Sciences, Proceedings of the National Academy of Sciences 1997 cited by 933

  22. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

    Authors: Howard A. Burris, Jeffrey R. Infante, Stephen M. Ansell, John Nemunaitis, Geoffrey R. Weiss, Víctor M. Villalobos, Branimir I. Šikić, Matthew H. Taylor, Donald W. Northfelt, William E. Carson, Thomas Hawthorne, Thomas A. Davis, Michael Yellin, Tibor Keler, Timothy N. J. Bullock - Journal of Clinical Oncology 2017 cited by 132

  23. Effect of spaceflight on human stem cell hematopoiesis: suppression of erythropoiesis and myelopoiesis

    Authors: Thomas A. Davis, William P. Wiesmann, William R. Kidwell, Tom Cannon, Laura Kerns, Catherine Serke, Ted Delaplaine, Alex Pranger, Kelvin P. Lee - Journal of Leukocyte Biology 1996 cited by 95

  24. The role of neutrophil extracellular traps and TLR signaling in skeletal muscle ischemia reperfusion injury

    Authors: Nicole Edwards, Charles Hwang, Simone Marini, Chase A. Pagani, Philip Spreadborough, Cassie J. Rowe, Pauline Yu, Annie Mei, Noelle D. Visser, Shuli Li, Geoffrey E. Hespe, Amanda K. Huber, Amy L. Strong, Miriam A. Shelef, Jason S. Knight, Thomas A. Davis, Benjamin Lévi - The FASEB Journal 2020 cited by 38